Skip to main content
. 2008 Jan;15(1):9–23. doi: 10.3747/co.2008.198

TABLE I.

Current guidelines for primary prophylaxis with granulocyte colony–stimulating factor (g-csf) 2–4

Neutropenic event risk ASCO 2006 2 EORTC 2006 3 NCCN 20064
Moderate to high Use G-CSF (~20%) Use G-CSF (≥20%) Use G-CSF (>20%)
Intermediate Recommend G-CSF (<20%) Consider G-CSF (10%–20%) Consider G-CSF (10%–20%)
Low Not specified G-CSF not recommended (<10%) G-CSF not recommended for most patients (<10%)
Risk factor assessment +++ +++ ++

asco = American Society of Clinical Oncology; eortc = European Organization for Research and Treatment of Cancer; nccn = National Comprehensive Cancer Network.